Integrated multiple-microarray analysis and mendelian randomization to identify novel targets involved in diabetic...

Area of Science:

• Genomics and Proteomics
• Nephrology
• Biomarker Discovery

Background:

• Diabetic nephropathy (DN) is a leading cause of end-stage renal disease globally.
• Mendelian randomization (MR) is a powerful genetic approach to infer causal relationships, minimizing confounding factors.
• Identifying reliable biomarkers and therapeutic targets for DN remains a significant clinical challenge.

Purpose of the Study:

• To integrate gene expression and proteomic data for novel biomarker identification in DN.
• To evaluate the causal effects of potential therapeutic targets for DN using large-scale MR analysis.
• To uncover underlying mechanisms and potential interventions for diabetic nephropathy.

Main Methods:

• Integrated analysis of five DN gene expression datasets using robust rank aggregation (RRA).
• Functional enrichment analysis of differentially expressed genes (DEGs).
• Two-sample Mendelian randomization (MR) analysis incorporating proteomic and DN genetic association data.

Main Results:

• Identified 82 differentially expressed genes (DEGs) in DN glomerular samples.
• MR analysis revealed causal associations between specific proteins (e.g., MICB, GZMA, FCN1) and DN risk.
• Expression validation indicated MICB, GZMA, FCN1, and IGF1 involvement in DN development, with CA2 and LPL showing protective roles.

Conclusions:

• Novel biomarkers, including MHC class I polypeptide-related sequence B (MICB) and granzyme A (GZMA), were identified for diabetic nephropathy.
• These findings enhance understanding of complex DN pathogenesis.
• The study highlights potential new target pathways for therapeutic intervention in DN.